Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 8:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 2,514 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sequence Clear all

Conditions: Healthy Participants
Interventions: TAK-994; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 2
States / cities: Tempe, Arizona • Lincoln, Nebraska

Conditions: Short Stature
Interventions: Vosoritide; Drug
Lead sponsor: Andrew Dauber; Other
Eligibility: 3 Years to 10 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2035
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Colorectal Cancer
Interventions: All eligible subjects will provide blood for SEPT9 biomarker testing; Other
Lead sponsor: Epigenomics, Inc; Industry
Eligibility: 50 Years and older
Enrollment: 7,929 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 20
States / cities: Boca Raton, Florida • Miami, Florida • Atlanta, Georgia + 15 more

Conditions: Pharmacokinetics
Interventions: 1 gram of a protein hydrolysate, 2 grams of a protein hydrolysate, 4 grams of a protein hydrolysate, 8 grams of a protein hydrolysate; Dietary Supplement
Lead sponsor: Natural Immune Systems Inc; Other
Eligibility: 25 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Klamath Falls, Oregon

Conditions: Chronic Neurogenic Pain
Interventions: Transcranial magnetic stimulation, Sham; Device · Other
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy Adults
Interventions: QRH-882260; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 25 Years to 100 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Healthy
Interventions: Palbociclib administered Fasted, Palbociclib administered Fed high calorie, Palbociclib administered Fed low calorie, Palbociclib administered Fed moderate calorie; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy Volunteer
Interventions: ABBV-CLS-616, Placebo, Itraconazole; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Primary Hypogonadism, Hypogonadotropic Hypogonadism
Interventions: Testosterone Topical Gel, 1.62% Metered Pump, AndroGel (testosterone gel) 1.62% Metered-Dose Pump; Drug
Lead sponsor: Amneal Pharmaceuticals, LLC; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Miami Gardens, Florida

Conditions: Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF)
Interventions: MS1819, Porcine PERT; Drug
Lead sponsor: Entero Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 10
States / cities: Long Beach, California • Altamonte Springs, Florida • Miami, Florida + 7 more

Conditions: Neoplasms
Interventions: Pimasertib Capsule (Part A), Pimasertib Tablet (Part A), Pimasertib Capsule (Part B and trial extension phase); Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Rockland, Massachusetts

Conditions: Healthy Volunteers
Interventions: TAK-906, Rifampin; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy Participants
Interventions: AZD5004; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 2
States / cities: Glendale, California • Baltimore, Maryland

Conditions: Pain
Interventions: VX-548; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Infertility
Interventions: PGD; Other
Lead sponsor: Reprogenetics; Industry
Eligibility: 18 Years to 42 Years · Female only
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Cardiac Amyloidosis
Interventions: 18F-Florbetaben (Neuraceq®) PET/MRI; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Stanford, California

Conditions: Genetic Diseases, Inborn
Interventions: Sequence; Other
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 1 Day and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Post Menopausal
Interventions: videodance, Brisk Walking, delayed entry control; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 50 Years to 65 Years · Female only
Enrollment: 168 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Pediatric Temperature
Interventions: Nasopharyngeal temperature probe; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 0 Years to 12 Years
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Revefenacin, Placebo, Formoterol; Drug
Lead sponsor: Mylan Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 12
States / cities: Miami, Florida • Orlando, Florida • Sarasota, Florida + 9 more

Conditions: Cardiovascular Risk, Cardiovascular Prevention
Interventions: CV Prevention Choice Tool, Implementation Facilitation Strategies; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 40 Years to 75 Years
Enrollment: 112,127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 4
States / cities: Marietta, Georgia • Rochester, Minnesota • Grand Forks, North Dakota + 1 more

Conditions: Type2diabetes
Interventions: high intensity body-weight circuit; Behavioral
Lead sponsor: Kennesaw State University; Other
Eligibility: 40 Years to 65 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Kennesaw, Georgia

Conditions: Healthy
Interventions: Relacorilant 350mg, Itraconazole, Relacorilant 300mg; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Drug Interaction
Interventions: Ecopipam, Cohort 1 Probe Substrate Cocktail, Cohort 2 Probe Substrate, Cohort 3 Probe Substrate Cocktail; Drug · Combination Product
Lead sponsor: Emalex Biosciences Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Search by objective public record fields.

A Study of Different Forms of TAK-994 in Healthy Adults

Vosoritide for Selected Genetic Causes of Short Stature

PRESEPT Study: Evaluation of SEPT9 Biomarker Performance for Colorectal Cancer Screening

Immunological Effect of Increasing Doses of Natural Peptide

Noninvasive Neuromodulation Of The Subjective Value Network In Chronic Pain

Study of the Safety of QRH-882260 Heptapeptide

Characterization Of The Effect Of Food On Palbociclib (PD-0332991) Absorption

A Study to Assess the Safety, Tolerability, and Interactions of ABBV-CLS-616 Oral Tablets in Healthy Adult Participants

Bioequivalence Study of Test and Reference Testosterone Topical Gel, 1.62% Metered Pump in Testosterone Deficient Adult Male Subjects Under Fasting Conditions

OPTION 2: A Trial to Assess the Safety and Efficacy of MS1819 in Enteric Capsules in Patients With Cystic Fibrosis

Relative Bioavailability of Pimasertib in Cancer Patients

A Study to Evaluate the Effect of Single-Dose Intravenous Rifampin as a Prototypic Inhibitor of Organic Anion Transporting Polypeptide (OATP) 1B1 and OATP1B3 on the Single-Dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants

A Study to Investigate the Pharmacokinetics of Different Formulations and Safety of AZD5004 in Healthy Participants Aged 18 to 55 Years

A Study to Evaluate the Effect of Food on the Pharmacokinetics of VX-548

Comparison of Frozen-thawed Embryo Transfers and Fresh Embryo Transfers With Whole Chromosome Analysis Using Next Generation Sequencing

PET/MRI Evaluation of Cardiac Amyloid

Whole Genome Sequencing in the Neonatal Intensive Care Unit

Adherence and Health Effects of Video Dance in Postmenopausal Women

Optimal Positioning of Nasopharyngeal Temp Probe

A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD

Implementing Shared Decision Making (SDM) For Individualized CV Prevention (SDM4IP)

High Intensity Body-weight Circuit Training Feasibility and Efficacy for in Middle Aged Persons With Type 2 Diabetes

Study in Healthy Subjects to Determine the Effect of an Inhibitor on Exposure to Relacorilant and Its Metabolites

Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates for Drug Metabolism and Transport